You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www. Prescription DEXILANT capsules are used in children age 12 to 17 years for 4 weeks to treat heartburn related to gastroesophageal reflux disease GERD , for up to 8 weeks to heal acid-related damage to the lining of the esophagus called erosive esophagitis or EE , and for up to 16 weeks to continue healing of EE and relief of heartburn.
In adults, persistent heartburn two or more days a week, despite treatment and diet changes, could be GERD, also known as acid reflux disease ARD. Most damage erosions heals in 4 to 8 weeks. Talk to your doctor or healthcare professional. The links to third-party websites contained on this website are provided solely for your convenience. Takeda does not control the content contained on any third-party website linked from this website.
Your activities on those websites will be governed by the policies and practices of those third parties. Just be sure to swallow the applesauce mixture right away. Don't chew the granules in the applesauce mixture and don't store it for later use. Not an actual patient. Important Safety Information. Glossary For Healthcare Professionals Sitemap.
The use of tacrolimus is very common in people who have undergone organ transplants. Taking tacrolimus with Dexilant can increase the amount of tacrolimus in your body. High amounts of tacrolimus can cause serious side effects, including kidney problems.
Rifampin is an antibiotic used to treat bacterial infections. Dexilant may not be effective in people taking rifampin. This is because rifampin decreases the amount of Dexilant in your body if you take these drugs together. They may ask you to stop taking rifampin and switch to a different antibiotic. Voriconazole is used in people with fungus infections. Taking voriconazole with Dexilant can increase the amounts of Dexilant in your body.
High amounts of Dexilant can cause side effects such as diarrhea and nausea. Taking antiretroviral drugs which treat HIV with Dexilant can affect the amount of antiretroviral drugs in your body.
Dexilant lowers the amount of some antiretrovirals in the body and increases the amount of others. Lower amounts of antiretrovirals in the body can make the drugs less effective. Higher amounts can raise your risk of side effects. Dexilant can also interact with the antiretroviral drug ritonavir. Ritonavir can increase the amount of Dexilant in your body. Some medications need a certain level of stomach acid to help them be absorbed in your blood.
Dexilant reduces the amounts of acid in your stomach. This may change the amounts of the other medications in your blood.
This change could make other drugs less effective or raise your risk of side effects. Dexilant can interact with the herb St. Lower amounts of Dexilant can make it less effective. Tell your doctor about all the herbs you take, including St. They can determine if those herbs are safe to take with Dexilant. There are no known interactions between Dexilant and alcohol. However, alcohol can cause acid reflux. This can worsen your symptoms of erosive esophagitis or gastroesophageal reflux disease GERD.
If you drink alcohol, talk with your doctor about how much alcohol is safe to drink with your condition. No clinical studies have been done to evaluate Dexilant use in pregnant people.
However, studies have looked at whether other proton pump inhibitors PPIs are safe to use during pregnancy. However, a study found that drugs which lower stomach acid may cause problems later on. When pregnant women took an acid-lowering drug, their babies were more likely to develop childhood asthma.
More research is needed to determine whether taking Dexilant during pregnancy causes childhood asthma. In animal studies , Dexilant was found safe for use in pregnant animals even at high doses. Also, let your doctor know if you become pregnant while taking Dexilant. They can help determine if Dexilant is safe for you to use during pregnancy. If you are sexually active and you or your partner can become pregnant, talk with your doctor about your birth control needs while using Dexilant.
Lansoprazole is a drug very similar to Dexilant. In animal studies , traces of lansoprazole were found in animal milk. The effects in the animal offspring are unknown. They can help determine if breastfeeding while taking Dexilant is safe for you and your child. As with all medications, the cost of Dexilant can vary. To find current prices for Dexilant in your area, check out GoodRx.
The cost you find on GoodRx. Your insurance plan may require you to get prior authorization before approving coverage for Dexilant. This means that your doctor will need to send a request to your insurance company asking them to cover the drug. The insurance company will review the request and let you and your doctor know if your plan will cover Dexilant. If you need financial support to pay for Dexilant, help is available. Takeda Pharmaceuticals America Inc.
Probably not. But if you stop taking Dexilant before your condition has improved, your symptoms may come back. Talk with your doctor if you want to stop taking Dexilant. They can help determine the safest way to stop taking it. This means you need to present a medical prescription to your pharmacist to get Dexilant.
However, other drugs similar to Dexilant can be purchased over the counter without a prescription. These drugs include lansoprazole Prevacid , esomeprazole Nexium , and omeprazole Prilosec. Yes, Dexilant can cure your erosive esophagitis. It can also relieve your symptoms of gastroesophageal reflux disease GERD. In some cases, you may have heartburn flare-ups or a return of other symptoms.
Dexilant will only reduce the amount of acid your stomach makes. This helps prevent symptoms like heartburn. You should take Dexilant for as long as your doctor prescribes it. Most people take Dexilant for 4 weeks to 6 months. Taking Dexilant long term may increase your risk of certain side effects.
Before taking Dexilant, talk with your doctor about your health history. Dexilant may not be right for you if you have certain medical conditions or other factors affecting your health.
These include:. They can monitor your condition and, if needed, prescribe medication to treat your symptoms. You can also call the American Association of Poison Control Centers at or use their online tool. But if your symptoms are severe, call or go to the nearest emergency room right away. When you get Dexilant from the pharmacy, the pharmacist will add an expiration date to the label on the bottle.
This date is typically 1 year from the date they dispensed the medication. The expiration date helps guarantee the medication will be effective during this time. If you have unused medication that has gone past the expiration date, talk to your pharmacist. You should store Dexilant in a tightly sealed container. Avoid storing Dexilant in areas where it could get damp or wet, such as bathrooms.
This helps prevent others, including children and pets, from taking the drug by accident. It also helps keep the drug from harming the environment. The FDA website provides several useful tips on medication disposal. You can also ask your pharmacist for information on how to dispose of your medication. Dexilant is an acid-modifier indicated to treat gastrointestinal disorders. This enzyme is considered a proton pump and is present at the surface of gastric parietal cells.
Through this inhibition, Dexilant blocks the secretion of gastric acid by the enzyme. The blockage interrupts the last step of the production of gastric acid.
The pharmacokinetics of Dexilant presents two peaks after its administration. The first peak is observed within 1 to 2 hours following the administration. The second peak occurs within 4 to 5 hours of Dexilant administration. After consecutive doses, Dexilant reaches a volume of distribution of 40 L. Dexilant undergoes extensive metabolization by enzymes from the P cytochrome. Dexilant is not renally excreted. The elimination half-life is 1 to 2 hours.
Current studies only involve children ages 12 to 17 years old. In children ages 12 to 17 years old, the overall exposure to Dexilant is slightly lower than in adult patients. The use of Dexilant is contraindicated in patients with hypersensitivity to any of its ingredients. Dexilant is also contraindicated in patients receiving treatment with rilpivirine.
Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication.
The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses. Gastroesophageal reflux disease GERD is a digestive condition in which the stomach's contents often come back up into the food pipe.
Dietary changes…. Heartburn is one symptom of the condition acid reflux. Chronic acid reflux may be diagnosed as gastroesophageal reflux disease, or GERD.
This article…. Many people with gastroesophageal reflux disease GERD experience fatigue because of the ways that the disease's symptoms impact sleep. In this…. Acid reflux is an uncomfortable condition in which stomach acid flows back into the food pipe. This article investigates which drinks will make it…. Both heartburn and heart attacks can cause pain in the center of the chest. Heartburn is a symptom of acid reflux and gastroesophageal reflux disease….
The study protocol was approved by the Ethics Committees of the above three hospitals. All patients provided written informed consent prior to participation. This clinical trial has been registered in a publicly accessible registry ClinicalTrials. We invited eligible outpatients to join our study. The outpatients were at least 18 years old, presented with clinical symptoms of acid regurgitation, heartburn, and a feeling of acidity in the stomach[ 10 ], and had endoscopy-confirmed LA grade A or B erosive esophagitis[ 11 , 12 ].
We enrolled a total of patients using strict inclusion criteria. The exclusion criteria included 1 those who had been taking antisecretory agents, such as PPIs and H 2 RA, within 2 wk prior to the endoscopy; 2 those who had coexistence of a peptic ulcer or gastrointestinal malignancies, and were pregnant; 3 those who had coexistence of a serious concomitant illness e.
Eligible patients were randomly assigned to receive either dexlansoprazole 60 mg q. Randomization was conducted using a computer-generated list of random numbers in a ratio into two sequence groups that defined the order in which the patients received a single dose of dexlansoprazole or esomeprazole for an intention-to-treat analysis.
An independent staff member assigned the treatments according to consecutive numbers kept in sealed envelopes. Written informed consent was obtained from each patient. Each patient completed diary cards during the study period. Complete symptom resolution CSR was defined as no reflux symptoms leading to troublesome feelings in the 7 d of initial treatment. The selected symptoms that best accounted for the differences between the patients with GERD and the controls included acid regurgitation, heartburn, and a feeling of acidity in the stomach.
Blood samples were collected to measure the fasting blood sugar, serum cholesterol, and triglyceride levels. In addition, the body mass index BMI was calculated. Upon initial endoscopy, specimens taken from the greater curvature within 5 cm from the pylorus and from the greater curvature of the middle body were subjected to a microscopic examination for Helicobacter pylori H.
No eradication therapy was administered during the study period. A complete medical history and demographic data were obtained from each patient. A gastric biopsy for histology and an H. The patients returned to the clinics for drug refills and evaluation of reflux symptoms after one week. Adverse events were prospectively evaluated. The adverse events were assessed according to a 4-point scale system as follows: none; mild discomfort, annoying but not interfering with daily work ; moderate discomfort sufficient to interfere with daily work ; and severe discomfort resulting in discontinuation of PPI therapy.
Compliance was checked by counting the unused medication at the completion of 7 d of treatment. CSR was defined as no reflux symptoms sufficient to impair the quality of life before the end of the initial treatment phase. The main outcome measures were the CSR rates at days 1, 3 and 7 of the initial treatment period. All patients who started esomeprazole or dexlansoprazole as their initial treatment were included in the intent-to-treat ITT analysis.
Patients with poor drug compliance were excluded from the per-protocol PP analysis. As a consequence of not achieving the target number, our study was a pilot study. The mean reflux symptom scores between groups were compared using the Wilcoxon rank sum test. All statistical analyses were performed using the SPSS program version A P value less than 0.
From April to March , two hundred and forty-three eligible symptomatic patients who had endoscopy-confirmed Los Angeles grade A or B erosive esophagitis were assessed. A total of 88 patients received the dexlansoprazole treatment, and 87 patients received the esomeprazole treatment.
At days 1, 3, and 7 post-dose, the CSR rates for the dexlansoprazole vs esomeprazole groups were In the subgroup analysis based on sex, females had higher CSR rates in the dexlansoprazole group at day 3 However, no significant differences were observed in the subgroup analyses based on age and body weight.
In addition, patients with a habit of consuming spicy foods had lower CSR rates No dependent factor was found on days 3 and 7. Multivariate analysis of the clinical factors predictive of complete symptom resolution within one week based on dexlansoprazole and esomeprazole administration.
Multivariate analysis of the clinical factors predictive of complete symptom resolution within one week. We conducted a randomized, controlled, open-label study to compare the 7-d clinical effects of single doses of dexlansoprazole 60 mg and esomeprazole 40 mg for GERD patients. We observed that the overall CSR rates for GERD patients were similar at days 1 through 7 of treatment for both the dexlansoprazole and esomeprazole groups. However, in our subgroup analysis based on sex, we observed that females had higher CSR rates in the dexlansoprazole group at day 3 We also found that patients with the habit of eating spicy foods had lower CSR rates Both dexlansoprazole and esomeprazole are potent PPIs for gastric acid suppression with excellent symptom relief for patients with GERD[ 14 - 19 ].
The advantage of dexlansoprazole MR Takeda Pharmaceuticals, Osaka, Japan is that it employs a novel approach by which its dual delayed-release DDR formulation prolongs the plasma concentration and ultimately extends the duration of acid suppression[ 14 ], thereby offering a twice-daily dosing effect in a one-time dose.
Conversely, esomeprazole 40 mg is a delayed-release formulation with single-release characteristics that produces maximum plasma concentrations at approximately 1. However, no direct head-to-head comparative report has investigated the short-term clinical effects or timing to symptom relief of GERD between dexlansoprazole at 60 mg and esomeprazole at 40 mg.
However, no significant differences were found in the healing rates of erosive esophagitis. Unfortunately, differences in the clinical effects between these two PPIs were not mentioned. At days 1, 3, and 7 post-dose, the CSR rates between the two groups were similar These findings implied that esomeprazole at 40 mg required more time 3 d than dexlansoprazole at 60 mg to attain CSR in females.
Several possible mechanisms may underlie these observations. First, both esomeprazole and dexlansoprazole are extensively metabolized in the liver by oxidation, reduction, and subsequent conversion of sulfate, glucuronide and glutathione conjugates to inactive metabolites. In the pharmacokinetics report of esomeprazole[ 24 ], the mean exposure AUC to esomeprazole increases from 4.
As a result, dexlansoprazole almost achieved the target concentration on day 1. Second, ample evidence has shown that estrogen and progestogen can enhance relaxation of the lower esophageal sphincters and induce GERD symptoms[ 28 - 30 ], especially in post-menopausal women taking hormone replacement therapy HRT [ 31 - 36 ].
These hypotheses might explain why female patients taking esomeprazole needed at least 3 more days to accumulate a sufficient plasma concentration to achieve plateau levels and desirable clinical effects. Another observation in this study was the lower CSR rates in patients with the habit of eating spicy foods in the esomeprazole group at day 1 after the multivariate analysis.
No reliable data are available in the existing literature regarding the role of diet or specific foods or drinks in GERD[ 37 ]. Some foods are believed to induce or worsen GERD symptoms in daily clinical practice, and this belief has led to advising patients to avoid the suspect foods[ 38 ]. Nebel et al[ 39 ] demonstrated that fried foods, spicy foods, and alcohol were the most common precipitating factors of heartburn, but this study had no control group and did not quantify the intake of dietary items.
In contrast, our study used a dietary questionnaire to estimate the frequency of the consumption of different types of food. In addition to the above shortcoming, this study has other limitations. As a result, the study may not represent the clinical effects of the entire GERD population.
Second, this study used dietary questionnaires to estimate the frequency of consumption of different types of foods but did not quantify the fat or carbohydrate content. Nonetheless, this pilot study is the first important report to compare the clinical efficacy of a one-week dual delayed-release treatment with dexlansoprazole at 60 mg and esomeprazole at 40 mg for grades A and B GERD patients, since fast symptomatic relief is an important unmet need in the treatment of GERD.
In conclusion, the overall CSR rates for GERD were similar at days 1 through 7 for both the dexlansoprazole and esomeprazole groups, although a higher CSR was observed at day 3 in female patients who received a single dose of dexlansoprazole. Since rapid onset of proton-pump inhibitors for fast symptom relief is an unmet need for the treatment of GERD and no report have investigated the short-term clinical effects of dexlansoprazole 60 mg vs esomeprazole 40 mg, this finding of this pilot study is novel.
Furthermore, these findings may have important implications for clinical practice when treating patients with grades A and B GERD.
This issue was hampered by the small sample size. Thus, we believe that large-scale comparative studies are necessary. Gastroesophageal reflux disease GERD is a common gastrointestinal disorder worldwide and continues to increase in incidence due to the aging population and obesity epidemic.
Rapid onset proton-pump inhibitors for fast symptom relief is an unmet need for GERD treatment. To date, no reports have investigated the short-term clinical effects and timing to symptom relief of gastroesophageal reflux disease GERD between dexlansoprazole 60 mg and esomeprazole 40 mg.
0コメント